Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Biometrics|September 1, 1988
A bayesian approach to the design of phase II clinical trialsR J Sylvester
Cancer Treatment Reports|February 1, 1980
Design of phase II clinical trials in cancer using decision theoryR J Sylvester, M J Staquet
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 25, 1999
Sample size estimation in phase III cancer clinical trialsD Curran, R J Sylvester, G Hoctin Boes
European Urology|March 31, 1998
The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative GroupR J Sylvester, L Denis, H de Voogt
Statistics in Medicine|April 29, 1998
Identifying the types of missingness in quality of life data from clinical trialsD Curran, M Bacchi, S F Schmitz, et al.
Statistical Methods in Medical Research|April 2, 2002
Analysing longitudinal continuous quality of life data with dropoutD Curran, G Molenberghs, N K Aaronson, et al.
Cancer|December 15, 1980
Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancerR Paridaens, R J Sylvester, E Ferrazzi, et al.
The Prostate|June 8, 2001
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differencesL Collette, U E Studer, F H Schröder, et al.
Cancer|May 1, 1977
Significance of quantitative assessment of estrogen receptors for endocrine therapy in advanced breast cancerJ C Heuson, E Longeval, W H Mattheiem, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating InvestigatorsP C Clahsen, C J van de Velde, K Welvaart, et al.
Pageof 2